StockData
RenovoRx, Inc. logo

RenovoRx, Inc. (RNXT) stock

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.95−0.09 (-8.18%)

Close on Nov 16, 2026Market cap $43.09MP/E –Yield –

RenovoRx operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

RenovoRx's operating cash flow for the twelve months ending Jun 30, 2026 was -$11.87M. For fiscal 2025 it was -$10.97M. The highest annual figure on record is -$3.53M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.97M–
FY2024Dec 31, 2024-$9.13M–
FY2023Dec 31, 2023-$10.26M–
FY2022Dec 31, 2022-$8.81M–
FY2021Dec 31, 2021-$5.92M–
FY2020Dec 31, 2020-$3.53M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.87M–
Q1 FY2026Mar 31, 2026-$3.71M–
Q4 FY2025Dec 31, 2025-$3.02M–
Q3 FY2025Sep 30, 2025-$2.27M–
Q2 FY2025Jun 30, 2025-$2.30M–
Q1 FY2025Mar 31, 2025-$3.38M–
Q4 FY2024Dec 31, 2024-$2.43M–
Q3 FY2024Sep 30, 2024-$2.19M–
Q2 FY2024Jun 30, 2024-$2.30M–
Q1 FY2024Mar 31, 2024-$2.20M–
Q4 FY2023Dec 31, 2023-$2.05M–
Q3 FY2023Sep 30, 2023-$2.73M–
Q2 FY2023Jun 30, 2023-$2.77M–
Q1 FY2023Mar 31, 2023-$2.71M–
Q4 FY2022Dec 31, 2022-$1.68M–
Q3 FY2022Sep 30, 2022-$2.67M–
Q2 FY2022Jun 30, 2022-$2.36M–
Q1 FY2022Mar 31, 2022-$2.10M–
Q4 FY2021Dec 31, 2021-$2.56M–
Q3 FY2021Sep 30, 2021-$1.12M–
Q2 FY2021Jun 30, 2021-$1.25M–
Q1 FY2021Mar 31, 2021-$992.00K–
Q4 FY2020Dec 31, 2020-$970.00K–

More RenovoRx figures

See a number that looks wrong?